Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Edward V. Connell"'
Autor:
Edward V. Connell, Djamal Abdurakhmanov, Igor G. Bakulin, Michael J. McKenna, Giovanni Faria Silva, Fernando Tatsch, Hugo Cheinquer, Wlodzimierz Mazur, Diethelm Messinger, K. Rajender Reddy, Stephen A. Harrison, Mitchell L. Shiffman, Maribel Rodriguez-Torres
Publikováno v:
Journal of clinical gastroenterology. 47(3)
Patients infected with hepatitis C virus (HCV) with elevated low-density lipoprotein (LDL) levels achieve higher sustained virologic response (SVR) rates after peginterferon (PegIFN)/ribavirin treatment versus patients with lower LDL. Our aim was to
Autor:
Andreas Tietz, Edward V. Connell, W. Graham E. Cooksley, A. Lin, Armand Abergel, Mark G. Swain, Moisés Diago, Douglas T. Dieterich, Ming–Yang Lai, Stefan Zeuzem, Mario G. Pessoa, Mitchell L. Shiffman
Publikováno v:
Gastroenterology. 139(5)
A sustained virologic response (SVR) to therapy for hepatitis C virus (HCV) infection is defined as the inability to detect HCV RNA 24 weeks after completion of treatment. Although small studies have reported that the SVR is durable and lasts for lon
Autor:
Karl Frank, Douglas D. Richman, Manfred Weigele, Edward V. Connell, Iain S. Sim, Donna M. Huryn, Hiroaki Mitsuya, Samuel Broder, Louis J. Todaro, Tam Steve Yik-Kai, Barbara C. Sluboski, Michael J. Holman
Publikováno v:
Annals of the New York Academy of Sciences. 616:408-414
Autor:
Richard L. Cerruti, R B Belshe, Percy S. Manchand, Iain S. Sim, Elizabeth Keech, Joseph A. Martin, Edward V. Connell, John Herbert Merrett, Hill Christopher Huw
Publikováno v:
Journal of Medicinal Chemistry. 33:1992-1995
The hydroxy metabolites of rimantadine (3-5) were synthesized and compared to amantadine (1) and rimantadine (2) for their ability to inhibit the replication of influenza viruses in vitro. All three metabolites were inhibitory to wild-type influenza
Publikováno v:
Antiviral Research. 5:217-223
Hairless mice were infected intracutaneously with HSV-1 and treated with rHuIFN-alpha A/D, a recombinant DNA-derived hybrid human interferon-alpha that is active on mouse cells in vitro and in vivo. When given alone (1 or 2 X 10(5) units/dose) at tim
Autor:
Michael J. Kramer, Patrick W. Trown, Palleroni Alicia Vallejo, Jorge R. Quesada, Robert A. Dennin, Jordan U. Gutterman, Edward V. Connell
Publikováno v:
Lancet (London, England). 1(8316)
During the course of clinical investigation of partly purified human leucocyte interferon (IFN) prepared at the Finnish Red Cross (PIF), neutralising IgG antibodies to human leucocyte IFN were detected in the sera of 3 patients with cancer. In 2 of t